ArticleOncology research2026
The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) are a cornerstone of systemic therapy for renal cell carcinoma (RCC), used both in the adjuvant and metastatic settings across various lines of treatment, often in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). These therapies are associated with endocrine immune-related adverse events (irAEs), which can be irreversible and life-threatening if not promptly managed. Using data from the Food and Drug Administration Adverse Reporting System (FAERS), this study aimed to evaluate the real-world occurrence of endocrine irAEs in all approved VEGFR-TKI + ICI combinations for RCC, and to compare these findings with the corresponding VEGFR-TKI or ICI monotherapies. The immune doublet ipilimumab + nivolumab was not considered in this analysis. Methods: FAERS database from 2019 Q1 to 2024 Q2 was queried using OpenVigil 2.1-MedDRA-v24 and AERS Results: Compared with VEGFR-TKI monotherapies, VEGFR-TKI + ICI combinations showed a significant disproportionate reporting of endocrine irAEs, mostly associated with the combination regimens. In contrast, when compared with ICI monotherapy, VEGFR-TKI + ICI showed more heterogeneous disproportionality signals, with generally lower reporting of hypothalamus, pituitary, and hyperglycemic disorders, whereas hypoglycemia and thyroid irAEs were more frequently reported, except for autoimmune thyroid diseases. Conclusion: Combination therapy, compared with VEGFR-TKI monotherapy, was associated with a higher reporting frequency of specific endocrine irAEs, whereas comparisons with ICI monotherapy yielded mixed signals, highlighting regimen- and event-specific differences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.